NASDAQ · Medical - Diagnostics & Research

Castle Biosciences, Inc. (CSTL) Stock

$34.42 +2.11% NASDAQ: CSTL Healthcare

Valuation

MetricValue
Price$34.42
Market Cap$1.05B
P/E Ratio-53.92
P/B Ratio2.30
P/S Ratio3.04
EPS (TTM)$0.00
52-Week High$44.28
52-Week Low$17.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-4.15%
ROA-3.46%
ROCE-6.36%
Gross Margin-12.50%
Operating Margin-12.50%
Net Margin-5.43%
Debt/Equity0.08
Current Ratio5.23

Annual Financials (USD)

Metric20212022202320242025
Revenue$94.0M$137.0M$220.0M$332.0M$344.0M
Operating Profit$-40.0M$-73.0M$-68.0M$9.0M$-43.0M
Net Profit$-31.0M$-67.0M$-57.0M$18.0M$-24.0M
EPS$-1.24$-2.58$-2.14$0.62$-0.83
Op Margin-42.6%-53.2%-30.9%2.6%-12.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$463.0M$447.0M$453.0M$531.0M$579.0M
Total Liabilities$51.0M$48.0M$62.0M$75.0M$108.0M
Cash$330.0M$123.0M$99.0M$120.0M$117.0M
Borrowings$8.0M$13.0M$15.0M$26.0M$37.0M

Latest News

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test PR Newswire · Jul 14, 2026 Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 PR Newswire · Jul 9, 2026 SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation Exec Edge · Jul 1, 2026 Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down Simply Wall St. · Jun 26, 2026 DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy PR Newswire · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-42.0M$-6.0M$65.0M$64.0M
Investing Cash Flow$-70.0M$-172.0M$-30.0M$-78.0M$-96.0M
Financing Cash Flow$5.0M$2.0M$-2.0M$-6.0M$-9.0M
Net Cash Flow$-80.0M$-207.0M$-24.0M$21.0M$-3.0M
Free Cash Flow$-22.0M$-47.0M$-19.0M$37.0M$28.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.54
EV / EBITDA-327.84
FCF Yield-0.05%
Quick Ratio5.85
Interest Coverage-85.62
Return 1Y51.67%
Return 3Y60.86%
Return 5Y-64.40%

Ownership

Insiders Held2.73%
Institutions Held92.43%
Institutions Float Held95.03%
Institutional HolderSharesReport Date
Blackrock Inc.2,982,9462026-03-31
RTW Investments LP2,758,3352026-03-31
Principal Financial Group, Inc.1,769,8772026-03-31
Portolan Capital Management, LLC1,350,2832026-03-31
Vanguard Capital Management LLC1,177,5222026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BDSXBiodesix, Inc. $26.02 +1.52% -8.74 $211.81M 0.00%
BIAFbioAffinity Technologies, Inc. $4.84 -14.18% -0.05 $2.03M 0.00%
FRNMFreenome, Inc. $15.78 -0.19% — $128.72M 0.00%
GHGuardant Health, Inc. $167.47 +1.15% -48.23 $22.47B 0.00%
MDXHMDxHealth SA $0.59 +1.58% -1.02 $30.29M 0.00%

About Castle Biosciences, Inc.

Castle Biosciences, Inc. is led by CEO Derek J. Maetzold, employs 784 people, headquartered in US, publicly traded since 2019.

Castle Biosciences, Inc. (CSTL) stock trades at $34.42 with a market capitalization of $1.05B. The stock is valued at a price-to-earnings (P/E) ratio of -53.92, price-to-book of 2.30, price-to-sales of 3.04. Over the past 52 weeks the stock has ranged between $17.72 and $44.28, and currently trades 22.3% below its 52-week high.

On profitability, Castle Biosciences, Inc. generates a return on equity (ROE) of -4.15%, return on capital employed of -6.36%, an operating margin of -12.50%, a net profit margin of -5.43%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides